JSC Grindeks is pleased to announce a significant milestone in its product portfolio expansion: the successful registration of betamethasone valerate cream in the United Kingdom. This achievement was authorised through the national registration procedure, marking the JSC Grindeks’s first corticosteroid product to enter the UK market. The betamethasone valerate cream product was developed by the JSC Grindeks R&D team in full compliance with the EMA regulatory requirements.
Manufacturing of betamethasone valerate cream has been successfully transferred to Tallinna Farmaatsiatehase AS (Tallinn Pharmaceutical Plant). The production unit has been built to ensure quality, manufacturing efficiency, and compliance with high regulatory standards for both our own proprietary medicines and JSC Grindeks’ contract products.
Tallinn Pharmaceutical Plant: is capable of producing more than 5 million tubes per year, ensuring high-precision manufacturing for potent active ingredients.
Beyond JSC Grindeks Group product portfolio, Tallinna Farmaatsiatehase AS remains a premier destination for contract manufacturing. With its advanced technological capabilities and available capacity, the plant is ideally positioned to undertake complex semi-solid product manufacturing for international partners.
